top of page
  • nabalunews


20 JAN 2021

KUALA LUMPUR: Chinese pharmaceutical company, Jemincare Group, has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralising antibody (JMB2002). Preclinical studies of JMB2002 including pharmacology and toxicity were carried out systemically. The drug metabolism, safety and efficacy were well performed, according to a statement. In early studies, it was found that JMB2002 could effectively neutralise live virus infection of Vero E6 cells and showed potent binding and blocking activities to the spike glycoproteins of mutant viruses.

While most of the SARS-CoV-2 neutralising antibodies in clinical trial are produced from cell pool, the product for clinical trial of JMB2002 is produced from high yield stable cell line, that ensures the consistency and stability of clinical samples. JMB2002 is derived from the naive human B cell antibody library of healthy donors. With the powerful phage-to-yeast platform, researchers quickly pinpoint the ideal candidates from over 10 billion antibody molecules in 19 days. Jemincare Group, making breakthrough achievements in the recent two years, has focused on the R&D of new drugs over the years with R&D pipeline for treating diseases in cancer, central nervous system, respiratory system, cardiovascular and cerebrovascular systems.

In 2018, Jemincare established its Research Institute in Shanghai Zhangjiang Science City and has recruited over 400 R&D scientists in five research centres for development of innovative drugs. - Bernama


bottom of page